Brendan Manning, Ph.D.

Brendan Manning, Ph.D.

Professor and Acting Chair, Department of Molecular Metabolism (Harvard T.H. Chan School of Public Health
Affiliate Member of Cell Biology (HMS)

Brendan Manning, Ph.D. is a Professor and Acting Chair in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award. 

Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.

665 Huntington Ave

SPH2-117

Boston, MA 02115

The multifaceted role of mTORC1 in the control of lipid metabolism.
Authors: Authors: Ricoult SJ, Manning BD.

View full abstract on Pubmed
The TSC-mTOR pathway regulates macrophage polarization.
Authors: Authors: Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T.
Nat Commun
View full abstract on Pubmed
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1.
Authors: Authors: Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD.
Mol Cell
View full abstract on Pubmed
Comment on "A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation": building a model of the mTOR signaling network with a potentially faulty tool.
Authors: Authors: Manning BD.
Sci Signal
View full abstract on Pubmed
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Authors: Authors: Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD.
Sci Signal
View full abstract on Pubmed
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Authors: Authors: Auricchio N, Malinowska I, Shaw R, Manning BD, Kwiatkowski DJ.
PLoS One
View full abstract on Pubmed
Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance.
Authors: Authors: Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.
Cancer Discov
View full abstract on Pubmed
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
Authors: Authors: De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K.
Cancer Cell
View full abstract on Pubmed
Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.
Authors: Authors: Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH, Manning BD.
Cell Metab
View full abstract on Pubmed
Transcriptional control of cellular metabolism by mTOR signaling.
Authors: Authors: Yecies JL, Manning BD.
Cancer Res
View full abstract on Pubmed